5PSQ-090 Anticholinergic drugs and acetylcholinesterase inhibitors: a non-recommended combination

BackgroundAnticholinergic drugs exert their effect by the opposite mechanism to acetylcholinesterase inhibitors (AChEIs), helping to counteract their modest efficacy and favouring the appearance of adverse events.PurposeTo determine the prevalence of patients with concomitant prescription of AChEIs...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2019-03, Vol.26 (Suppl 1), p.A243-A243
Hauptverfasser: Oro Fernandez, M, Valencia Soto, CM, Gutierrez Revilla, JI, Perez Hernandez, F, Tejerina, A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A243
container_issue Suppl 1
container_start_page A243
container_title European journal of hospital pharmacy. Science and practice
container_volume 26
creator Oro Fernandez, M
Valencia Soto, CM
Gutierrez Revilla, JI
Perez Hernandez, F
Tejerina, A
description BackgroundAnticholinergic drugs exert their effect by the opposite mechanism to acetylcholinesterase inhibitors (AChEIs), helping to counteract their modest efficacy and favouring the appearance of adverse events.PurposeTo determine the prevalence of patients with concomitant prescription of AChEIs and anticholinergics in an institutionalised population and to analyse their associated characteristics.Material and methodsCross-sectional descriptive study carried out in August 2018 including patients from three nursing homes with concomitant prescription of AChEIs and anticholinergic drugs.Variables were: age, sex, number of drugs, Charlson Index Score (ChI), presence, type and level of cognitive disorder (CD) and anticholinergic and AChEI prescribed.To identify anticholinergic drugs we used The Anticholinergic-Cognitive-Burden (ACB) scale. Accumulated score ≥3 was considered elevated. To evaluate CD, we used the global deterioration scale (GDS), considering valid the scores from the past 18 months.ResultsWe found 219 patients with CD out of our 367 sample. 22.,4% patients with the concomitant prescription (n=49) were selected. Average age was 86.4±5.3, 79.6% (n=39) females. Average ChI score was 6.2±1.2 and the median number of drugs nine (2–17).Regarding diagnosis: 43% Alzheimer’s disease, 28,6% mixed dementia, 18,4% Lewy–Body dementia and 10% others.The deterioration degree was 36.7% from moderately-severe to severe cognitive decline, 12.2% from severe to very severe and 3% from mild to moderate and from moderate to moderately-severe. This data was not available/updated in 38.8% patients.Rivastigmine (53%) was the most prescribed AChEI, followed by donepezil (35%) and galantine (12%). Anticholinergics were prescribed in 71% (n=35) patients with AChEI. Eighty-five per cent (n=30) had elevated AB.A total of 67 prescriptions of anticholinergic drugs were detected (1.91/patient). Eighty-two per cent belonged to ‘Nervous System’(ATC N). Sixteen prescriptions corresponded to drugs with 3 points on the ACB scale. Quetiapine (87.5%) was the most prescribed. The remaining 51 corresponded to drugs with 1 point. Trazodone (47%) was the most frequently implicated drug.No statistically significant differences in taking anticholinergic drugs were found between those taking AChEIs or not.ConclusionAlmost half of our population presented an important/severe CD degree. Concomitant prescription of anticholinergics and AChEIs was frequent. Drugs from NS were the most implic
doi_str_mv 10.1136/ejhpharm-2019-eahpconf.523
format Article
fullrecord <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2190001827</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2190001827</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1263-d8deaf638f72e6df206ed85fb78d5a6dec0c73bf35d8f0084395aebc71c590be3</originalsourceid><addsrcrecordid>eNo9kMtKAzEYhYMoWGrfYdB1ai5NJnFXijcoqKjrkGsnpZMZM9NFd258UZ_EKW1dnQPn8P-HD4BrjKYYU37r11Vb6VxDgrCEXletbVKYMkLPwIigWQml5LPzf8_4JZh0XTSIUSrkjMoRsOz1_Q0iiX6_f-apj7ZqNjH5vIq2cHm76gqdXKGt73ebY9b1PuvOFzFV0cS-yd1doYvUJJi9beraJ-ddMTgTk-5jk67ARdCbzk-OOgafD_cfiye4fHl8XsyX0GDCKXTCeR04FaEknrtAEPdOsGBK4ZjmzltkS2oCZU4EhMSwn2lvbIktk8h4OgY3h7ttbr62w061brY5DS8VwRIhhAUphxY7tEy9Vm2Otc47hZHaI1UnpGqPVJ2QqgEp_QMaS3Ip</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2190001827</pqid></control><display><type>article</type><title>5PSQ-090 Anticholinergic drugs and acetylcholinesterase inhibitors: a non-recommended combination</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Oro Fernandez, M ; Valencia Soto, CM ; Gutierrez Revilla, JI ; Perez Hernandez, F ; Tejerina, A</creator><creatorcontrib>Oro Fernandez, M ; Valencia Soto, CM ; Gutierrez Revilla, JI ; Perez Hernandez, F ; Tejerina, A</creatorcontrib><description>BackgroundAnticholinergic drugs exert their effect by the opposite mechanism to acetylcholinesterase inhibitors (AChEIs), helping to counteract their modest efficacy and favouring the appearance of adverse events.PurposeTo determine the prevalence of patients with concomitant prescription of AChEIs and anticholinergics in an institutionalised population and to analyse their associated characteristics.Material and methodsCross-sectional descriptive study carried out in August 2018 including patients from three nursing homes with concomitant prescription of AChEIs and anticholinergic drugs.Variables were: age, sex, number of drugs, Charlson Index Score (ChI), presence, type and level of cognitive disorder (CD) and anticholinergic and AChEI prescribed.To identify anticholinergic drugs we used The Anticholinergic-Cognitive-Burden (ACB) scale. Accumulated score ≥3 was considered elevated. To evaluate CD, we used the global deterioration scale (GDS), considering valid the scores from the past 18 months.ResultsWe found 219 patients with CD out of our 367 sample. 22.,4% patients with the concomitant prescription (n=49) were selected. Average age was 86.4±5.3, 79.6% (n=39) females. Average ChI score was 6.2±1.2 and the median number of drugs nine (2–17).Regarding diagnosis: 43% Alzheimer’s disease, 28,6% mixed dementia, 18,4% Lewy–Body dementia and 10% others.The deterioration degree was 36.7% from moderately-severe to severe cognitive decline, 12.2% from severe to very severe and 3% from mild to moderate and from moderate to moderately-severe. This data was not available/updated in 38.8% patients.Rivastigmine (53%) was the most prescribed AChEI, followed by donepezil (35%) and galantine (12%). Anticholinergics were prescribed in 71% (n=35) patients with AChEI. Eighty-five per cent (n=30) had elevated AB.A total of 67 prescriptions of anticholinergic drugs were detected (1.91/patient). Eighty-two per cent belonged to ‘Nervous System’(ATC N). Sixteen prescriptions corresponded to drugs with 3 points on the ACB scale. Quetiapine (87.5%) was the most prescribed. The remaining 51 corresponded to drugs with 1 point. Trazodone (47%) was the most frequently implicated drug.No statistically significant differences in taking anticholinergic drugs were found between those taking AChEIs or not.ConclusionAlmost half of our population presented an important/severe CD degree. Concomitant prescription of anticholinergics and AChEIs was frequent. Drugs from NS were the most implicated. It was not more likely to take anticholinergics among those taking AChEIs.A reappraisal of the therapeutic approach should be periodically considered in this vulnerable group of patients.References and/or acknowledgementsNo conflict of interest</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2019-eahpconf.523</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Dementia ; Prescription drugs</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A243-A243</ispartof><rights>2019, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2019 2019, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Oro Fernandez, M</creatorcontrib><creatorcontrib>Valencia Soto, CM</creatorcontrib><creatorcontrib>Gutierrez Revilla, JI</creatorcontrib><creatorcontrib>Perez Hernandez, F</creatorcontrib><creatorcontrib>Tejerina, A</creatorcontrib><title>5PSQ-090 Anticholinergic drugs and acetylcholinesterase inhibitors: a non-recommended combination</title><title>European journal of hospital pharmacy. Science and practice</title><description>BackgroundAnticholinergic drugs exert their effect by the opposite mechanism to acetylcholinesterase inhibitors (AChEIs), helping to counteract their modest efficacy and favouring the appearance of adverse events.PurposeTo determine the prevalence of patients with concomitant prescription of AChEIs and anticholinergics in an institutionalised population and to analyse their associated characteristics.Material and methodsCross-sectional descriptive study carried out in August 2018 including patients from three nursing homes with concomitant prescription of AChEIs and anticholinergic drugs.Variables were: age, sex, number of drugs, Charlson Index Score (ChI), presence, type and level of cognitive disorder (CD) and anticholinergic and AChEI prescribed.To identify anticholinergic drugs we used The Anticholinergic-Cognitive-Burden (ACB) scale. Accumulated score ≥3 was considered elevated. To evaluate CD, we used the global deterioration scale (GDS), considering valid the scores from the past 18 months.ResultsWe found 219 patients with CD out of our 367 sample. 22.,4% patients with the concomitant prescription (n=49) were selected. Average age was 86.4±5.3, 79.6% (n=39) females. Average ChI score was 6.2±1.2 and the median number of drugs nine (2–17).Regarding diagnosis: 43% Alzheimer’s disease, 28,6% mixed dementia, 18,4% Lewy–Body dementia and 10% others.The deterioration degree was 36.7% from moderately-severe to severe cognitive decline, 12.2% from severe to very severe and 3% from mild to moderate and from moderate to moderately-severe. This data was not available/updated in 38.8% patients.Rivastigmine (53%) was the most prescribed AChEI, followed by donepezil (35%) and galantine (12%). Anticholinergics were prescribed in 71% (n=35) patients with AChEI. Eighty-five per cent (n=30) had elevated AB.A total of 67 prescriptions of anticholinergic drugs were detected (1.91/patient). Eighty-two per cent belonged to ‘Nervous System’(ATC N). Sixteen prescriptions corresponded to drugs with 3 points on the ACB scale. Quetiapine (87.5%) was the most prescribed. The remaining 51 corresponded to drugs with 1 point. Trazodone (47%) was the most frequently implicated drug.No statistically significant differences in taking anticholinergic drugs were found between those taking AChEIs or not.ConclusionAlmost half of our population presented an important/severe CD degree. Concomitant prescription of anticholinergics and AChEIs was frequent. Drugs from NS were the most implicated. It was not more likely to take anticholinergics among those taking AChEIs.A reappraisal of the therapeutic approach should be periodically considered in this vulnerable group of patients.References and/or acknowledgementsNo conflict of interest</description><subject>Dementia</subject><subject>Prescription drugs</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo9kMtKAzEYhYMoWGrfYdB1ai5NJnFXijcoqKjrkGsnpZMZM9NFd258UZ_EKW1dnQPn8P-HD4BrjKYYU37r11Vb6VxDgrCEXletbVKYMkLPwIigWQml5LPzf8_4JZh0XTSIUSrkjMoRsOz1_Q0iiX6_f-apj7ZqNjH5vIq2cHm76gqdXKGt73ebY9b1PuvOFzFV0cS-yd1doYvUJJi9beraJ-ddMTgTk-5jk67ARdCbzk-OOgafD_cfiye4fHl8XsyX0GDCKXTCeR04FaEknrtAEPdOsGBK4ZjmzltkS2oCZU4EhMSwn2lvbIktk8h4OgY3h7ttbr62w061brY5DS8VwRIhhAUphxY7tEy9Vm2Otc47hZHaI1UnpGqPVJ2QqgEp_QMaS3Ip</recordid><startdate>201903</startdate><enddate>201903</enddate><creator>Oro Fernandez, M</creator><creator>Valencia Soto, CM</creator><creator>Gutierrez Revilla, JI</creator><creator>Perez Hernandez, F</creator><creator>Tejerina, A</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201903</creationdate><title>5PSQ-090 Anticholinergic drugs and acetylcholinesterase inhibitors: a non-recommended combination</title><author>Oro Fernandez, M ; Valencia Soto, CM ; Gutierrez Revilla, JI ; Perez Hernandez, F ; Tejerina, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1263-d8deaf638f72e6df206ed85fb78d5a6dec0c73bf35d8f0084395aebc71c590be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Dementia</topic><topic>Prescription drugs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oro Fernandez, M</creatorcontrib><creatorcontrib>Valencia Soto, CM</creatorcontrib><creatorcontrib>Gutierrez Revilla, JI</creatorcontrib><creatorcontrib>Perez Hernandez, F</creatorcontrib><creatorcontrib>Tejerina, A</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oro Fernandez, M</au><au>Valencia Soto, CM</au><au>Gutierrez Revilla, JI</au><au>Perez Hernandez, F</au><au>Tejerina, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>5PSQ-090 Anticholinergic drugs and acetylcholinesterase inhibitors: a non-recommended combination</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2019-03</date><risdate>2019</risdate><volume>26</volume><issue>Suppl 1</issue><spage>A243</spage><epage>A243</epage><pages>A243-A243</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>BackgroundAnticholinergic drugs exert their effect by the opposite mechanism to acetylcholinesterase inhibitors (AChEIs), helping to counteract their modest efficacy and favouring the appearance of adverse events.PurposeTo determine the prevalence of patients with concomitant prescription of AChEIs and anticholinergics in an institutionalised population and to analyse their associated characteristics.Material and methodsCross-sectional descriptive study carried out in August 2018 including patients from three nursing homes with concomitant prescription of AChEIs and anticholinergic drugs.Variables were: age, sex, number of drugs, Charlson Index Score (ChI), presence, type and level of cognitive disorder (CD) and anticholinergic and AChEI prescribed.To identify anticholinergic drugs we used The Anticholinergic-Cognitive-Burden (ACB) scale. Accumulated score ≥3 was considered elevated. To evaluate CD, we used the global deterioration scale (GDS), considering valid the scores from the past 18 months.ResultsWe found 219 patients with CD out of our 367 sample. 22.,4% patients with the concomitant prescription (n=49) were selected. Average age was 86.4±5.3, 79.6% (n=39) females. Average ChI score was 6.2±1.2 and the median number of drugs nine (2–17).Regarding diagnosis: 43% Alzheimer’s disease, 28,6% mixed dementia, 18,4% Lewy–Body dementia and 10% others.The deterioration degree was 36.7% from moderately-severe to severe cognitive decline, 12.2% from severe to very severe and 3% from mild to moderate and from moderate to moderately-severe. This data was not available/updated in 38.8% patients.Rivastigmine (53%) was the most prescribed AChEI, followed by donepezil (35%) and galantine (12%). Anticholinergics were prescribed in 71% (n=35) patients with AChEI. Eighty-five per cent (n=30) had elevated AB.A total of 67 prescriptions of anticholinergic drugs were detected (1.91/patient). Eighty-two per cent belonged to ‘Nervous System’(ATC N). Sixteen prescriptions corresponded to drugs with 3 points on the ACB scale. Quetiapine (87.5%) was the most prescribed. The remaining 51 corresponded to drugs with 1 point. Trazodone (47%) was the most frequently implicated drug.No statistically significant differences in taking anticholinergic drugs were found between those taking AChEIs or not.ConclusionAlmost half of our population presented an important/severe CD degree. Concomitant prescription of anticholinergics and AChEIs was frequent. Drugs from NS were the most implicated. It was not more likely to take anticholinergics among those taking AChEIs.A reappraisal of the therapeutic approach should be periodically considered in this vulnerable group of patients.References and/or acknowledgementsNo conflict of interest</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2019-eahpconf.523</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2047-9956
ispartof European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A243-A243
issn 2047-9956
2047-9964
language eng
recordid cdi_proquest_journals_2190001827
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Dementia
Prescription drugs
title 5PSQ-090 Anticholinergic drugs and acetylcholinesterase inhibitors: a non-recommended combination
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T15%3A37%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=5PSQ-090%E2%80%85Anticholinergic%20drugs%20and%20acetylcholinesterase%20inhibitors:%20a%20non-recommended%20combination&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Oro%20Fernandez,%20M&rft.date=2019-03&rft.volume=26&rft.issue=Suppl%201&rft.spage=A243&rft.epage=A243&rft.pages=A243-A243&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2019-eahpconf.523&rft_dat=%3Cproquest_bmj_p%3E2190001827%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2190001827&rft_id=info:pmid/&rfr_iscdi=true